Sign In
Buy ZYME
$24.35
+0.240 (+1.00%)
At Close: Jun 03, 2026
Zymeworks Inc. (ZYME) Q1 2024 Earnings Call Transcript
08:04pm, Thursday, 02'nd May 2024
Zymeworks Inc. (NASDAQ:ZYME ) Q1 2024 Earnings Call Transcript May 2, 2024 4:30 PM ET Company Participants Shrinal Inamdar - Director, Investor Relations Ken Galbraith - Chair and CEO Paul Moore - Chi
Zymeworks Inc. (ZYME) Reports Q1 Loss, Misses Revenue Estimates
07:41pm, Thursday, 02'nd May 2024
Zymeworks Inc. (ZYME) came out with a quarterly loss of $0.42 per share versus the Zacks Consensus Estimate of a loss of $0.31. This compares to loss of $0.37 per share a year ago.
ATTENTION Zymeworks Inc. Investors: You May Have Been Affected by Fraud - Contact Levi & Korsinsky to Discuss Your Rights
11:00am, Thursday, 02'nd May 2024
NEW YORK, NY / ACCESSWIRE / May 2, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Zymeworks Inc. ("Zymeworks") (NASDAQ:ZYME) concerning possible violations of fed
Zymeworks Announces Participation in Upcoming Investor Conferences
06:00am, Tuesday, 30'th Apr 2024
VANCOUVER, British Columbia, April 30, 2024 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherape
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Zymeworks Inc. - ZYME
09:45am, Sunday, 28'th Apr 2024
NEW YORK , April 28, 2024 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Zymeworks Inc. ("Zymeworks" or the "Company") (NASDAQ: ZYME). Such investors are advised to c
3 Top Stocks to Invest in for Amazing Earnings Acceleration
08:01am, Thursday, 25'th Apr 2024
Invest in companies such as Zymeworks (ZYME), Evolus (EOLS) and Bilibili (BILI) for superb earnings acceleration.
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Zymeworks Inc. - ZYME
12:15pm, Saturday, 20'th Apr 2024
NEW YORK , April 20, 2024 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Zymeworks Inc. ("Zymeworks" or the "Company") (NASDAQ: ZYME). Such investors are advised to co
NEW YORK, NY / ACCESSWIRE / April 19, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Zymeworks Inc. ("Zymeworks") (NASDAQ:ZYME) concerning possible violations of
Buy Zymeworks Pioneering Cancer Treatments: Zanidatamab's Promising Data
03:06pm, Thursday, 18'th Apr 2024
Zymeworks is a biotechnology company that develops innovative therapies for difficult-to-treat cancers and serious conditions. The company's flagship drug, Zanidatamab, is in phase 3 clinical trials a
Zymeworks To Report First Quarter 2024 Financial Results and Host Conference Call on May 2, 2024
06:00am, Thursday, 11'th Apr 2024
VANCOUVER, British Columbia, April 11, 2024 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherape
Zymeworks (ZYME) Loses -13.41% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
10:36am, Wednesday, 10'th Apr 2024
Zymeworks (ZYME) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising
Zymeworks Announces Participation in Upcoming Investor Conferences
06:00am, Wednesday, 27'th Mar 2024
VANCOUVER, British Columbia, March 27, 2024 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherape
Zymeworks (ZYME) Upgraded to Buy: What Does It Mean for the Stock?
01:01pm, Friday, 22'nd Mar 2024
Zymeworks (ZYME) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Next-Gen Winners: 7 Tech Stocks Set to Dominate the Decade
10:18am, Friday, 08'th Mar 2024
In the stock markets, fortunes rise and fall on the tide of hype and advancements, with the tech sector impacted the most. As the world is in the middle of a decade, the stage is set for the listed te
Zymeworks Inc. (ZYME) Q4 2023 Earnings Call Transcript
11:17pm, Wednesday, 06'th Mar 2024
Zymeworks Inc. (NASDAQ:ZYME ) Q4 2023 Earnings Conference Call March 6, 2024 4:30 PM ET Company Participants Shrinal Inamdar - Director, Investor Relations Dr. Chris Astle - Senior Vice President and
